The Ruby Trial: A Review

Cabo blood in Puckley-Taxel is effective in under-metrial cancer but it's a short term efficacy and if you look at the median overall survival it's less than three years. The first drug we had introduced was in 1961, protestants and after that about 15 years ago we introduced CaboBlood in Puckly-Taxel - nothing has happened really since then. We know that chemotherapy enhances the efficacy of immune therapies. It makes a lot of sense to test Cabo blood in Pucksley- taxel in the combination of immune checkpoint inhibitor here the Stalema which is a PD-1 both in the MMR deficient as well as in overall population.